

DAFTAR PUSTAKA

- Bader, R. M., Jonas, M. M., Mitchell, P. D., Wiggins, S., & Lee, C. K. (2019). Controlled attenuation parameter: A measure of hepatic steatosis in patients with cystic fibrosis. *Journal of Cystic Fibrosis*, 18(2), 280–285. <https://doi.org/10.1016/J.JCF.2018.11.004>
- Chen, J., Wang, M.-L., Long, Q., Bai, L., & Tang, H. (2017). High value of controlled attenuation parameter predicts a poor antiviral response in patients with chronic hepatitis B. *Hepatobiliary & Pancreatic Diseases International*, 16(4), 370–374. [https://doi.org/10.1016/S1499-3872\(16\)60144-3](https://doi.org/10.1016/S1499-3872(16)60144-3)
- Chen, X., Zhou, J., Wu, L., Zhu, X., & Deng, H. (2022). MAFLD is Associated with the Risk of Liver Fibrosis and Inflammatory Activity in HBeAg-Negative CHB Patients. *Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy*, Volume 15, 673–683. <https://doi.org/10.2147/DMSO.S351492>
- Cuomo, G., Iandoli, C., Galiero, R., Caturano, A., Di Vico, C., Perretta, D., Adamo, P. V., Ferrara, R., Rinaldi, L., Romano, C., & Sasso, F. C. (2023). Liver Involvement in Patients with Systemic Sclerosis: Role of Transient Elastography in the Assessment of Hepatic Fibrosis and Steatosis. *Diagnostics*, 13(10), 1–13. <https://doi.org/10.3390/diagnostics13101766>
- Deeb Khouri, L., & Shammaa, M. (2001). Alcoholic liver disease. *Journal Medical Libanais*, 49(2), 94–100.
- Dhurandhar, N. V. (2022). What is obesity? *International Journal of Obesity*, 46(6), 1081–1082. <https://doi.org/10.1038/s41366-022-01088-1>
- Elbrolosy, A. M., Elabd, N. S., ElGedawy, G. A., Abozeid, M., Abdelkreem, M., Montaser, B., Eed, E. M., & Elhamouly, M. S. (2022a). Toll- like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: a case control study in Egyptian patients. *Clinical and Experimental Medicine*. <https://doi.org/10.1007/s10238-022-00792-6>
- Elbrolosy, A. M., Elabd, N. S., ElGedawy, G. A., Abozeid, M., Abdelkreem, M., Montaser, B., Eed, E. M., & Elhamouly, M. S. (2022b). Toll- like receptor 2 polymorphism and IL-6 profile in relation to disease progression in chronic HBV infection: a case control study in Egyptian patients. *Clinical and Experimental Medicine*. <https://doi.org/10.1007/s10238-022-00792-6>
- Enomoto, H., Aizawa, N., Nishikawa, H., Ikeda, N., Sakai, Y., Takata, R., Hasegawa, K., Nakano, C., Nishimura, T., Yoh, K., Ishii, A., Takashima, T., Iwata, Y., Iijima, H., & Nishiguchi, S. (2016). Relationship Between Hepatic Steatosis and the Elevation of Aminotransferases in HBV-Infected Patients With HBe-Antigen Negativity and a Low Viral Load. *Medicine*, 95(17), e3565. <https://doi.org/10.1097/MD.0000000000003565>

- Fahed, G., Aoun, L., Bou Zerdan, M., Allam, S., Bou Zerdan, M., Bouferraa, Y., & Assi, H. I. (2022). Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. *International Journal of Molecular Sciences*, 23(2), 786. <https://doi.org/10.3390/ijms23020786>
- Fang, J. M., Cheng, J., Chang, M. F., Ahn, J., & Westerhoff, M. (2021). Transient elastography versus liver biopsy: discordance in evaluations for fibrosis and steatosis from a pathology standpoint. *Modern Pathology*, 34(10), 1955–1962. <https://doi.org/10.1038/s41379-021-00851-5>
- Ferraioli, G., & Monteiro, L. B. S. (2019). Ultrasound-based techniques for the diagnosis of liver steatosis. *World Journal of Gastroenterology*, 25(40), 6053–6062. <https://doi.org/10.3748/wjg.v25.i40.6053>
- Fibrosis (Scarring)*. (n.d.). AMERICAN LIVER FOUNDATION. <https://liverfoundation.org/about-your-liver/how-liver-diseases-progress/fibrosis-scarring/>
- Gangireddy, V. G. R., Pilkerton, C., Xiang, J., Tinajero, R., & Ashcraft, A. M. (2022). Hepatic Fibrosis and Steatosis in Metabolic Syndrome. *Journal of Obesity & Metabolic Syndrome*, 31(1), 61–69. <https://doi.org/10.7570/jomes21062>
- Gara, N., Tana, M. M., Kattapuram, M., Auh, S., Sullivan, L., Fryzek, N., Walter, M., Umarova, R., Zhao, X., Cloherty, G., Doo, E., Heller, T., Liang, J. T., & Ghany, M. G. (2021). Prospective Study of Withdrawal of Antiviral Therapy in Patients with Chronic Hepatitis B after Prolonged Virological Response. *Hepatology Communications*, 5(11), 1888–1900. <https://doi.org/10.1002/hep4.1761>
- Gerges, S. H., Wahdan, S. A., Elsherbiny, D. A., & El-Demerdash, E. (2021). Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions. *Life Sciences*, 271, 119220. <https://doi.org/10.1016/j.lfs.2021.119220>
- Gofton, C., Upendran, Y., Zheng, M.-H., & George, J. (2023a). MAFLD: How is it different from NAFLD? *Clinical and Molecular Hepatology*, 29(Suppl), S17–S31. <https://doi.org/10.3350/cmh.2022.0367>
- Gofton, C., Upendran, Y., Zheng, M.-H., & George, J. (2023b). MAFLD: How is it different from NAFLD? *Clinical and Molecular Hepatology*, 29(Suppl), S17–S31. <https://doi.org/10.3350/cmh.2022.0367>
- Hu, D., Wang, P., Wang, X., Hu, X., Huang, D., Yan, W., Xi, D., Han, M., Ning, Q., & Wang, H. (2024). The efficacy of antiviral treatment in chronic hepatitis B patients with hepatic steatosis. *Heliyon*, 10(7), e28653. <https://doi.org/10.1016/j.heliyon.2024.e28653>
- Hu, Y.-Y., Dong, N.-L., Qu, Q., Zhao, X.-F., & Yang, H.-J. (2018). The correlation between controlled attenuation parameter and metabolic syndrome and its components in middle-aged and elderly nonalcoholic fatty liver disease patients. *Medicine*, 97(43), e12931. <https://doi.org/10.1097/MD.00000000000012931>
- Idilman, I. S., Ozdeniz, I., & Karcaaltincaba, M. (2016a). Hepatic Steatosis: Etiology,

- Patterns, and Quantification. *Seminars in Ultrasound, CT and MRI*, 37(6), 501–510. <https://doi.org/10.1053/j.sult.2016.08.003>
- Idilman, I. S., Ozdeniz, I., & Karcaaltincaba, M. (2016b). Hepatic Steatosis: Etiology, Patterns, and Quantification. *Seminars in Ultrasound, CT and MRI*, 37(6), 501–510. <https://doi.org/10.1053/j.sult.2016.08.003>
- Jiang, D., Chen, C., Liu, X., Huang, C., Yan, D., Zhang, X., Zhou, Y., Lin, Y., Zhou, Y., Guan, Z., Ding, C., Lan, L., Zhu, C., Wu, J., Li, L., & Yang, S. (2021). Concurrence and impact of hepatic steatosis on chronic hepatitis B patients: a systematic review and meta-analysis. *Annals of Translational Medicine*, 9(23), 1718–1718. <https://doi.org/10.21037/atm-21-3052>
- Kechagias, S., Ekstedt, M., Simonsson, C., & Nasr, P. (2022). Non-invasive diagnosis and staging of non-alcoholic fatty liver disease. *Hormones*, 21(3), 349–368. <https://doi.org/10.1007/s42000-022-00377-8>
- Kemkes. (2022). *Hepatitis Can't Wait*. P2p.Kemkes. <http://p2p.kemkes.go.id/hepatitis-cant-wait/>
- Khanmohammadi, S., & Kuchay, M. S. (2022). Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease. *Pharmacological Research*, 185, 106507. <https://doi.org/10.1016/j.phrs.2022.106507>
- Kim, D. S., Jeon, M. Y., Lee, H. W., Kim, B. K., Park, J. Y., Kim, D. Y., Ahn, S. H., Han, K.-H., & Kim, S. U. (2019). Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir. *Clinical and Molecular Hepatology*, 25(3), 283–293. <https://doi.org/10.3350/cmh.2018.0054>
- Ko, H. H., Patel, N. H., Haylock-Jacobs, S., Doucette, K., Ma, M. M., Cooper, C., Kelly, E., Elkhatab, M., Tam, E., Bailey, R., Wong, A., Minuk, G., Wong, P., Fung, S. K., Sebastiani, G., Ramji, A., & Coffin, C. S. (2022). Severe Hepatic Steatosis Is Associated With Low-Level Viremia and Advanced Fibrosis in Patients With Chronic Hepatitis B in North America. *Gastro Hep Advances*, 1(1), 106–116. <https://doi.org/10.1016/j.gastha.2021.09.005>
- Liang, T. J. (2009). Hepatitis B: The virus and disease. *Hepatology*, 49(S5), S13–S21. <https://doi.org/10.1002/hep.22881>
- Liebe, R., Esposito, I., Bock, H. H., vom Dahl, S., Stindt, J., Baumann, U., Luedde, T., & Keitel, V. (2021). Diagnosis and management of secondary causes of steatohepatitis. *Journal of Hepatology*, 74(6), 1455–1471. <https://doi.org/10.1016/j.jhep.2021.01.045>
- Liu, L., Li, H., Zhang, Y., Zhang, J., & Cao, Z. (2023). Hepatitis B virus infection combined with nonalcoholic fatty liver disease: Interaction and prognosis. *Heliyon*, 9(1), e13113. <https://doi.org/10.1016/j.heliyon.2023.e13113>
- Liu, S.-Y., Wang, D., Liu, J., Yang, L.-P., & Chen, G.-Y. (2024a). Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis. *World Journal of Hepatology*, 16(3), 465–476. <https://doi.org/10.4254/wjh.v16.i3.465>

Liu, S.-Y., Wang, D., Liu, J., Yang, L.-P., & Chen, G.-Y. (2024b). Influence of nonalcoholic fatty liver disease on response to antiviral treatment in patients with chronic hepatitis B: A meta-analysis. *World Journal of Hepatology*, 16(3), 465–476. <https://doi.org/10.4254/wjh.v16.i3.465>

LiverScreen. (2021). *Controlled Attenuation Parameter (CAP) and its promising role in clinical practice*. <https://www.liverscreen.eu/clinical-corner/controlled-attenuation-parameter-cap-and-its-promising-role-in-clinical-practice-1/>

Lunova, M., Frankova, S., Gottfriedova, H., Senkerikova, R., Neroldova, M., Kovac, J., Kieslichova, E., Lanska, V., Sticova, E., Spicak, J., Jirsa, M., & Sperl, J. (2021). Portal hypertension is the main driver of liver stiffness in advanced liver cirrhosis. *Physiological Research*, 563–577. <https://doi.org/10.33549/physiolres.934626>

Mak, L.-Y., Hui, R. W.-H., Fung, J., Liu, F., Wong, D. K.-H., Cheung, K.-S., Yuen, M.-F., & Seto, W.-K. (2020). Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. *Journal of Hepatology*, 73(4), 800–806. <https://doi.org/10.1016/j.jhep.2020.05.040>

Medas, R., Liberal, R., & Macedo, G. (2021). Discontinuation of antiviral therapy in chronic hepatitis B patients. *World Journal of Clinical Cases*, 9(24), 6979–6986. <https://doi.org/10.12998/wjcc.v9.i24.6979>

Mysore, K. R., & Leung, D. H. (2018). Hepatitis B and C. *Clinics in Liver Disease*, 22(4), 703–722. <https://doi.org/10.1016/j.cld.2018.06.002>

Nagaoki, Y., Sugiyama, A., Mino, M., Kodama, H., Abe, K., Imada, H., Ouoba, S., E, B., Ko, K., Akita, T., Sako, T., Kumada, T., Chayama, K., & Tanaka, J. (2022). Prevalence of fatty liver and advanced fibrosis by ultrasonography and FibroScan in a general population random sample. *Hepatology Research*, 52(11), 908–918. <https://doi.org/10.1111/hepr.13821>

Nassir, F., Rector, R. S., Hammoud, G. M., & Ibdah, J. A. (2015). Pathogenesis and Prevention of Hepatic Steatosis. *Gastroenterology & Hepatology*, 11(3), 167–175. <http://www.ncbi.nlm.nih.gov/pubmed/27099587>

Pattyn, J., Hendrickx, G., Vorsters, A., & Van Damme, P. (2021). Hepatitis B Vaccines. *The Journal of Infectious Diseases*, 224(Supplement_4), S343–S351. <https://doi.org/10.1093/infdis/jiaa668>

Peleg, N., Issachar, A., Sneh Arbib, O., Cohen-Naftaly, M., Braun, M., Leshno, M., Barsheshet, A., & Shlomai, A. (2019). Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. *JHEP Reports*, 1(1), 9–16. <https://doi.org/10.1016/j.jhep.2019.02.002>

Prevention and Diagnosis of Hepatitis B. (2023). Hepatitis B Fondation. <https://www.hepb.org/prevention-and-diagnosis/diagnosis/other-tests/#:~:text=HBeAg>

publichealthlab. (2023). *HBeAg (Hepatitis B e-antigen)*. Newfoundland& Labrador Public Health Laboratory.

<https://publichealthlab.ca/reportingname/hbeag-hepatitis-b-e-antigen/#:~:text=HBe Ag is first detectable in,viral replication in acute infection.>

S., N., Y., L., Y., Q., F., L., L., W., & T., L. (2019). Hepatic steatosis in chronic hepatitis B as measured by controlled attenuation parameter: Frequency and distribution. *Journal of the College of Physicians and Surgeons Pakistan*, 29(10), 937–941. <http://www.embase.com/search/results?subaction=viewrecord&from=export&id=L629727958>

Schwabe, R. F., Tabas, I., & Pajvani, U. B. (2020). Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis. *Gastroenterology*, 158(7), 1913–1928. <https://doi.org/10.1053/j.gastro.2019.11.311>

Sefa Sayar, M., Bulut, D., & Acar, A. (2023). Evaluation of hepatosteatosi in patients with chronic hepatitis B virus infection. *Arab Journal of Gastroenterology*, 24(1), 11–15. <https://doi.org/10.1016/J.AJG.2022.05.002>

Sehgal, R., Mittal, J., & Singh, I. (2020). Correlation of Hepatic Steatosis with Hepatic Fibrosis in NAFLD Patients by Fibroscan. *Asian Journal of Medical Research*, 9(3), 1–7. <https://doi.org/10.47009/ajmr.2020.9.3.me1>

Senussi, N. H., & McCarthy, D. M. (2021). Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH). *Annals of Hepatology*, 24, 100526. <https://doi.org/10.1016/j.aohep.2021.100526>

Seto, W.-K., Hui, R. W. H., Mak, L.-Y., Fung, J., Cheung, K.-S., Liu, K. S. H., Wong, D. K.-H., Lai, C.-L., & Yuen, M.-F. (2018). Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. *Clinical Gastroenterology and Hepatology*, 16(4), 575–583.e2. <https://doi.org/10.1016/j.cgh.2017.09.044>

Shi, Y.-W., Yang, R.-X., & Fan, J.-G. (2021a). Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. *World Journal of Gastroenterology*, 27(26), 3971–3983. <https://doi.org/10.3748/wjg.v27.i26.3971>

Shi, Y.-W., Yang, R.-X., & Fan, J.-G. (2021b). Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion. *World Journal of Gastroenterology*, 27(26), 3971–3983. <https://doi.org/10.3748/wjg.v27.i26.3971>

Sulaiman, A. S. (2023). Perlemakan Hati Non-Alkoholik dan Risiko Fibrosis Hati pada Pasien Hepatitis B Kronik. *Jurnal Penyakit Dalam Indonesia*, 10(3). <https://doi.org/10.7454/jpdi.v10i3.1456>

Swarup, S., Goyal, A., Grigorova, Y., & Zeltser, R. (2023). Metabolic Syndrome. In *StatPearls*. <http://www.ncbi.nlm.nih.gov/pubmed/30278295>

Trifan, A., Stratina, E., Nastasa, R., Rotaru, A., Stafie, R., Zenovia, S., Huiban, L., Sfarti, C., Cojocariu, C., Cuciureanu, T., Muzica, C., Chiriac, S., Girleanu, I., Singeap, A.-M., & Stanciu, C. (2022). Simultaneously Screening for Liver Steatosis and Fibrosis in Romanian Type 2 Diabetes Mellitus Patients Using Vibration-Controlled Transient Elastography with Controlled Attenuation

Parameter. *Diagnostics*, 12(7), 1753. <https://doi.org/10.3390/diagnostics12071753>

Unger, L. W., Forstner, B., Muckenhuber, M., Scheuba, K., Eigenbauer, E., Scheiner, B., Pfisterer, N., Paternostro, R., Trauner, M., Mandorfer, M., & Reiberger, T. (2020). Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. *Digestive Diseases and Sciences*, 65(9), 2712–2718. <https://doi.org/10.1007/s10620-019-06000-y>

Wang, J., He, W., Tsai, P.-J., Chen, P.-H., Ye, M., Guo, J., & Su, Z. (2020). Mutual interaction between endoplasmic reticulum and mitochondria in nonalcoholic fatty liver disease. *Lipids in Health and Disease*, 19(1), 72. <https://doi.org/10.1186/s12944-020-01210-0>

WHO. (2020). *Hepatitis: Preventing mother-to-child transmission of the hepatitis B virus*. World Health Organization. <https://www.who.int/news-room/questions-and-answers/item/hepatitis-preventing-mother-to-child-transmission-of-the-hepatitis-b-virus>

WHO. (2022). *Hepatitis B*. WHO. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-b>

Woziwodzka, A., Rybicka, M., Sznarkowska, A., Romanowski, T., Dręczewski, M., Stalke, P., & Bielawski, K. P. (2019). TNF- α polymorphisms affect persistence and progression of HBV infection. *Molecular Genetics & Genomic Medicine*, 7(10). <https://doi.org/10.1002/mgg3.935>

Yi, S., Ren, G., Zhu, Y., & Cong, Q. (2024). Correlation analysis of hepatic steatosis and hepatitis B virus: a cross-sectional study. *Virology Journal*, 21(1), 22. <https://doi.org/10.1186/s12985-023-02277-8>

Yusuf, F., Abubakar, A., Maghfirah, D., & Baswin, A. (2021). Relationship red distribution width to platelet ratio with fibrosis degrees based on transient elastography in chronic hepatitis B patients. *Bali Medical Journal*, 10(2), 793–797. <https://doi.org/10.15562/bmj.v10i2.2355>

Zhang, Q. Q., & Lu, L. G. (2015). Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy. *Journal of Clinical and Translational Hepatology*, 3(1), 78–84. <https://doi.org/10.14218/JCTH.2014.00037>

Zhang, S., Zhang, X., Jin, H., Dou, Y., Li, L., Yuan, X., Dong, C., Hou, M., Nan, Y., & Shang, J. (2022). Adverse Effect of Nonalcoholic Fatty Liver Disease on the Therapeutic Response in Patients with Chronic Hepatitis B. *Journal of Clinical and Translational Hepatology*, 000(000), 000–000. <https://doi.org/10.14218/JCTH.2022.00066>

Zheng, Q., Zou, B., Wu, Y., Yeo, Y., Wu, H., Stave, C. D., Cheung, R. C., & Nguyen, M. H. (2021a). Systematic review with meta-analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. *Alimentary Pharmacology & Therapeutics*, 54(9), 1100–1109. <https://doi.org/10.1111/apt.16595>

Zheng, Q., Zou, B., Wu, Y., Yeo, Y., Wu, H., Stave, C. D., Cheung, R. C., & Nguyen, M. H. (2021b). Systematic review with meta-analysis: prevalence of hepatic steatosis,

fibrosis and associated factors in chronic hepatitis B. *Alimentary Pharmacology & Therapeutics*, 54(9), 1100–1109. <https://doi.org/10.1111/apt.16595>

Zheng, R., Xu, C., Jiang, L., Dou, A., Zhou, K., & Lu, L. (2010). Predictors of hepatic steatosis in HBeAg-negative chronic hepatitis B patients and their diagnostic values in hepatic fibrosis. *International Journal of Medical Sciences*, 272–277. <https://doi.org/10.7150/ijms.7.272>